CRAIG MARTIN CREWS, Ph.D.
John C. Malone Professor of Molecular, Cellular, and Developmental Biology
Department of Chemistry
Department of Pharmacology
Yale University
Education
| 1987-1993 |
Ph.D., Biochemistry, Harvard University (thesis project: Purification/cloning of MEK1) |
| 1986-1987 |
DAAD Fellow, Universität Tübingen, Germany |
| 1982-1986 |
B.A., Chemistry, University of Virginia |
Professional Experience
| 2021- |
Founder, Siduma Therapeutics, LLC |
| 2018- |
John C. Malone Professor of Molecular, Cellular, and Developmental Biology |
| 2018- |
Founder,Halda Therapeutics, LLC |
| 2013 |
Founder, Arvinas, Inc. (oncology-focused biotech) |
| 2010- |
Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology |
| 2003 |
Co-Founder, Proteolix |
| 2003- |
Executive Director, Yale Small Molecule Discovery Center |
| 2003 |
PI, NIH T32 Chemistry and Biology Interface (CBI) Training Grant (T32GM067543) |
| 2001-2007 |
Associate Professor → Professor, Yale University, Dept of Chemistry |
| 1998-2007 |
Assistant Professor → Professor, Yale School of Medicine, Dept of Pharmacology |
| 1995-2007 |
Assistant Professor → Professor, Yale University, Dept of Molecular, Cellular & Developmental Biology (tenured 2001) |
| 1993-1995 |
Postdoctoral Fellow, Dept. of Chemistry, Harvard University |
Honors and Awards
| 2024 |
Kimberly Prize in Biochemistry and Molecular Genetics, Northwestern School of Medicine
|
| 2023 |
Bristol Myers Squibb Award in Enzyme Chemistry, American Chemical Society
|
| 2023 |
Jacob and Louise Gabbay Award in Biotechnology and Medicine, Brandeis University
|
| 2022 |
Connecticut Medal of Technology, Connecticut Academy of Sciences and Engineering
|
| 2021 |
Honorary Doctorate (Dr. h. c.), Technische Universität Dortmund, Germany
|
| 2021 |
Scheele Prize, Swedish Pharmaceutical Society |
| 2020 |
Heinrich Wieland Laureate 2020, Boehringer Ingelheim Foundation |
| 2019 |
American Cancer Society Research Professorship |
| 2019 |
Pharmacia-ASPET Award for Experimental Therapeutics |
| 2018 |
Pierre Fabre Award for Therapeutic Innovation |
| 2018 |
Khorana Prize, Royal Society of Chemistry |
| 2017 |
AACR Award for Outstanding Achievement in Chemistry in Cancer Research |
| 2015 |
NIH R35 Outstanding Investigator Award (National Cancer Institute) |
| 2014 |
UCB-Ehrlich Award for Excellence in Medicinal Chemistry (Eur. Fed. of Med. Chemistry) |
| 2006 |
Bessel Research Award, Alexander von Humboldt Foundation, Germany |
Editorial Boards
Cell Chemical Biology, ACS Chemical Biology, ChemBioChem, Molecular Biosystems, Chemistry & Biology, Molecular and Cellular Proteomics
Patents
'Enzyme Inhibition' Patent US 6,831,099 B1
'Enzyme Inhibition' Patent US 7,476,650
'Proteolysis-Targeting Chimeric Pharmaceutical' Patent US 7,041,298
'Proteolysis-Targeting Chimeric Pharmaceutical' Patent US 7,208,157
'Compounds for Enzyme Inhibition' Patent US 7,232,818
'Compounds for Enzyme Inhibition' Patent US 7,491,704
'Compounds for Enzyme Inhibition' Patent US 8,088,741
'Compounds for Enzyme Inhibition' Patent US 8,129,346
FDA Approved Drugs
Carfilzomib/Kyprolis™ (based on the YU101 structure): approved for relapsed multiple myeloma (7/20/12)
H Index (Google Scholar) : 102
Laboratory Website
http://www.yale.edu/crews
Complete CV
Abbreviated CV